PTPRB and angiosarcoma: Recurrent driver mutations have been identified in the PTPRB or PLCG1 gene in 38% angiosarcoma patients, including primary and secondary tumors, which reinforce therapeutic efforts to target angiogenesis signaling in angiosarcoma [2].